Understanding and Managing Withdrawal Syndromes After Discontinuation of Antidepressant Drugs
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Withdrawal symptoms commonly occur during tapering and/or after discontinuation of antidepressant drugs, particularly selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors. Withdrawal symptomatology does not necessarily subside within a few weeks and may be associated with other manifestations of behavioral toxicity (loss of treatment efficacy, refractoriness, switch into mania/hypomania, or paradoxical reactions). The oppositional model of tolerance provides a pathophysiologic basis for understanding and managing withdrawal syndromes. Reintroducing the antidepressant that was initially used or switching from one antidepressant to another to suppress symptomatology, as suggested by current guidelines, may actually aggravate the state of behavioral toxicity and be detrimental in the long run. Alternative strategies that do not encompass continuation of antidepressant treatment are required, but there is currently lack of adequate research for guiding the clinical approach. Some tentative suggestions are provided.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A specific subgroup of the acute withdrawal syndrome is the rebound disorder, where previously known symptoms reoccur with greater intensity (Cosci and Chouinard, 2020; Fava and Cosci, 2019).”
From Post-acute withdrawal syndrome (PAWS) after stopping antidepressants: a systematic review with meta-narrative synthesis (2025) · cites this paper as Fava and Cosci, 2019
In the citing paper
“The prolonged use of antidepressant medications, similar to other psychotropic substances, can lead to sustained neurophysiological adaptations (Ashton, 1991; Cosci and Chouinard, 2020; Fava and Cosci, 2019; Horowitz et al., 2023; Lerner and Klein, 2019).”
From Post-acute withdrawal syndrome (PAWS) after stopping antidepressants: a systematic review with meta-narrative synthesis (2025) · cites this paper as Fava and Cosci, 2019
In the citing paper
“One recently identified main concern is the potential for acute and persistent post-acute (protracted) withdrawal symptoms when the medication is discontinued (Boland et al., 2024; Chouinard and Chouinard, 2015; Fava and Cosci, 2019; Hengartner et al., 2019; Lerner and Klein, 2019; Massabki and Abi-Jaoude, 2021).”
From Post-acute withdrawal syndrome (PAWS) after stopping antidepressants: a systematic review with meta-narrative synthesis (2025) · cites this paper as Fava and Cosci, 2019
In the citing paper
“Rather, characteristics of the individual may be more important; posited, among other potentially predisposing factors, are lengthy drug treatment, medication switches, abrupt discontinuation, inadequate tapering, prior difficulty in withdrawal or other adverse drug events and physiological vulnerability.20,23,30,41–43”
From Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum (2020) · cites this paper as [30]
In the citing paper
“The narratives analyzed in this study likewise indicate that consumers are able to distinguish drug withdrawal from the symptoms of the original illness, since withdrawal symptoms are experienced as more intense, urgent, and often unprecedented, that is, qualitatively different.28,30,35”
From Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum (2020) · cites this paper as [30]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Mechanisms of stress in the brain
McEwen, B. S., Bowles, N. P., Gray, J. D., Hill, M. N., Hunter, R. G., Karatsoreos, I. N., & Nasca, C. (2015) · Nature Neuroscience · doi:10.1038/nn.4086 · Cited by 1,386
Cuthbert, B. N. (2014) · World Psychiatry · doi:10.1002/wps.20087 · Cited by 1,377
X-ray structures and mechanism of the human serotonin transporter
Coleman, J. A., Green, E. M., & Gouaux, E. (2016) · Nature · doi:10.1038/nature17629 · Cited by 668
Carvalho, A. F., Sharma, M. S., Brunoni, A. R., Vieta, E., & Fava, G. A. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000447034 · Cited by 650
Self-citationExploring comorbidity within mental disorders among a Danish national population
Plana-Ripoll, O., Pedersen, C. B., Holtz, Y., Benros, M. E., Dalsgaard, S., de Jonge, P., Fan, C. C., Degenhardt, L., Ganna, A., Greve, A. N., et al. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.3658 · Cited by 584
Davies, J., & Read, J. (2019) · Addictive Behaviors · doi:10.1016/j.addbeh.2018.08.027 · Cited by 387
Antidepressant discontinuation reactions: Are preventable and simple to treat
Haddad, P., Lejoyeux, M., & Young, A. (1998) · BMJ · doi:10.1136/bmj.316.7138.1105 · Cited by 286
Tapering of SSRI treatment to mitigate withdrawal symptoms
Horowitz, M. A., & Taylor, D. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30032-x · Cited by 280
Can long-term treatment with antidepressant drugs worsen the course of depression?
Fava, G. A. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0204 · Cited by 223
Self-citationFava, G. A., Benasi, G., Lucente, M., Offidani, E., Cosci, F., & Guidi, J. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000491524 · Cited by 209
Self-citation
Cited by
Time for united action on depression: a Lancet–World Psychiatric Association Commission
Herrman, H., Patel, V., Kieling, C., Berk, M., Buchweitz, C., Cuijpers, P., Furukawa, T. A., Kessler, R. C., Kohrt, B. A., Maj, M., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02141-3 · Cited by 1,104
Effect of Electroacupuncture on Insomnia in Patients With Depression: A Randomized Clinical Trial
Yin, X., Li, W., Liang, T., Lu, B., Yue, H., Li, S., Zhong, V. W., Zhang, W., Li, X., Zhou, S., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.20563 · Cited by 159
Gastaldon, C., Schoretsanitis, G., Arzenton, E., Raschi, E., Papola, D., Ostuzzi, G., Moretti, U., Seifritz, E., Kane, J. M., Trifirò, G., et al. (2022) · Drug Safety · doi:10.1007/s40264-022-01246-4 · Cited by 64
Hengartner, M. P., Schulthess, L., Sorensen, A., & Framer, A. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320980573 · Cited by 74
Hengartner, M. P. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320921694 · Cited by 72
Trends in Antidepressant Use and Expenditure in Six Major Cities in China From 2013 to 2018
Yu, Z., Zhang, J., Zheng, Y., & Yu, L. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00551 · Cited by 67
Groot, P. C., & van Os, J. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320932452 · Cited by 49
Pharmacological treatments in panic disorder in adults: a network meta-analysis
Guaiana, G., Meader, N., Barbui, C., Davies, S., Furukawa, T. A., Imai, H., Dias, S., Caldwell, D. M., Koesters, M., Tajika, A., et al. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012729.pub3 · Cited by 47
Quilichini, J.-B., Revet, A., Garcia, P., Bouquié, R., Hamard, J., Yrondi, A., & Montastruc, F. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.10.041 · Cited by 47
Dold, M., Bartova, L., Volz, H., Seifritz, E., Möller, H., Schläfke, S., & Kasper, S. F. (2023) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-022-01547-w · Cited by 35
Antidepressant discontinuation syndrome: A state-of-the-art clinical review
Fornaro, M., Cattaneo, C. I., Berardis, D. D., Ressico, F. V., Martinotti, G., & Vieta, E. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.10.005 · Cited by 35
(2025) · doi:10.1038/s41380-024-02782-4 · Cited by 32
Psychotherapy in recurrent depression: efficacy, pitfalls, and recommendations
Cosci, F., Guidi, J., Mansueto, G., & Fava, G. A. (2020) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2020.1804870 · Cited by 31
Self-citationCosci, F., Mansueto, G., & Fava, G. A. (2020) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2020.1779308 · Cited by 29
Self-citationHorowitz, M. A., Buckman, J. E. J., Saunders, R., Aguirre, E., Davies, J., & Moncrieff, J. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116497 · Cited by 25
Sørensen, A., Jørgensen, K. J., & Munkholm, K. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.08.011 · Cited by 25
Andrade, C. (2022) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.22f14593 · Cited by 22
Villanueva, V., Artal, J., Cabeza‐Alvarez, C., Campos, D., Castillo, A., Flórez, G., Franco, M., García‐Portilla, M. P., Giráldez, B. G., Gotor, F., et al. (2023) · Neurology and Therapy · doi:10.1007/s40120-023-00437-0 · Cited by 22
Selective Serotonin Reuptake Inhibitors: How Long Is Long Enough?
Thom, R. P., Alexander, J. L., Baron, D. A., Garakani, A., Gross, L. S., Pine, J. H., Radhakrishnan, R., Slaby, A. E., & Sumner, C. R. (2021) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000578 · Cited by 21
Kufel, W. D., Parsels, K. A., Blaine, B. E., Steele, J. M., Seabury, R. W., & Asiago‐Reddy, E. (2023) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2023.106843 · Cited by 20
Discontinuing antidepressants: Pearls and pitfalls
Zwiebel, S. J., & Viguera, A. C. (2022) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.89a.21020 · Cited by 20
Treating depression in clinical practice: new insights on the multidisciplinary use of trazodone
Albert, U., Tomasetti, C., Marra, C., Neviani, F., Pirani, A., Taddeo, D., Zanetti, O. O., & Maina, G. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1207621 · Cited by 20
Patient Health Questionnaire-9: a clinimetric analysis
Cosci, F., Christensen, K. S., Ceccatelli, S., Patierno, C., & Carrozzino, D. (2024) · Brazilian Journal of Psychiatry · doi:10.47626/1516-4446-2023-3449 · Cited by 19
Self-citationPrescribing Pharmacotherapy for Major Depressive Disorder: How Does a Clinician Decide?
Cosci, F., & Fava, G. A. (2021) · Biomedicine Hub · doi:10.1159/000519656 · Cited by 19
Self-citationNeuromodulators in the Brain-Gut Axis: their Role in the Therapy of the Irritable Bowel Syndrome
Stănculete, M. F., Dumitrascu, D. L., & Drossman, D. A. (2021) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld-4090 · Cited by 19
Vaismoradi, M., Mardani, A., Lillo‐Crespo, M., Logan, P., & Sak‐Dankosky, N. (2024) · Therapeutic Advances in Drug Safety · doi:10.1177/20420986241289205 · Cited by 18
Pharmakotherapie von Angsterkrankungen – leitliniengerechte Therapie und Neuentwicklungen
Zwanzger, P., Singewald, N., & Bandelow, B. (2021) · Der Nervenarzt · doi:10.1007/s00115-020-01051-3 · Cited by 17
Stefanou, M., Vittore, D., Wolz, I., Klingberg, S., & Wildgruber, D. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00318 · Cited by 17
Cosci, F., Romanazzo, S., Mansueto, G., Rontani, P., Levitan, M. N., Halkjœr-Lassen, R. D., Quagliato, L. A., Nakamura, T., Uematsu, K., Nardi, A. E., et al. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001491 · Cited by 16
Self-citationThe Decline of Pluralism in Medicine: Dissent Is Welcome
Fava, G. A. (2019) · Psychotherapy and Psychosomatics · doi:10.1159/000505085 · Cited by 15
Self-citationPatacchini, A., & Cosci, F. (2021) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-200074 · Cited by 12
Self-citationCosci, F., Chouinard, V.-A., & Chouinard, G. (2024) · Psychotherapy and Psychosomatics · doi:10.1159/000540031 · Cited by 11
Self-citationFournier, J. C. J., Forand, N. R., Wang, Z., Li, Z., Iyengar, S., DeRubeis, R. J., Shelton, R. C., Amsterdam, J. D., Jarrett, R. B., Vittengl, J. R., et al. (2022) · Cognitive Therapy and Research · doi:10.1007/s10608-021-10281-x · Cited by 11
Andrews, P. W., & Amsterdam, J. D. (2020) · Psychiatria Polska · doi:10.12740/pp/120084 · Cited by 11
Two Sides of Depression: Medical & Social
Horwitz, A. V., & Wakefield, J. C. (2023) · Daedalus · doi:10.1162/daed_a_02039 · Cited by 9
Rennwald, A., & Hengartner, M. P. (2025) · Epidemiology and Psychiatric Sciences · doi:10.1017/s204579602500023x · Cited by 8
“The prolonged use of antidepressant medications, similar to other psychotropic substances, can lead to sustained neurophysiological adaptations (Ashton, 1991; Cosci and Chouinard, 2020; Fava and Cosci, 2019; Horowitz et al. , 2023; Lerner and Klein, 2019).”
InfluentialWang, Q., Cheng, L., Wu, B.-Y., Xu, P., Qiu, H.-Y., Wang, B., Yan, X.-J., & Chen, S. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1063722 · Cited by 8
Depression and Anxiety Disorders
Karamustafalıoğlu, O., & Yumrukçal, H. (2025) · Wiley eBooks · doi:10.1002/9781119870203.mpg003.pub2 · Cited by 8
Cosci, F., Chouinard, V., & Chouinard, G. (2023) · Psychotherapy and Psychosomatics · doi:10.1159/000530692 · Cited by 7
Self-citationAn update on pharmacotherapy for recurrent depression in 2022
Belge, J.-B., Sabbe, A. C. F., & Sabbe, B. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2223962 · Cited by 7
Dold, M., Möller, H., Volz, H., Seifritz, E., Schläfke, S., Bartova, L., & Kasper, S. F. (2024) · European Psychiatry · doi:10.1192/j.eurpsy.2024.16 · Cited by 7
Tercer Consenso Argentino sobre el manejo de los Trastornos Bipolares. Segunda Parte B
Cetkovich, M., Abadi, A. F., Camino, S., Bonetto, G. G., Herbst, L., Marengo, E., Torrente, F. M., Maresca, T., Bustin, J., Morra, C. A., et al. (2023) · Vertex Revista Argentina de Psiquiatría · doi:10.53680/vertex.v34i160.459 · Cited by 5
A risk identification model for detection of patients at risk of antidepressant discontinuation
Zolnour, A., Eldredge, C. E., Faiola, A. J., Yaghoobzadeh, Y., Khani, M., Foy, D., Topaz, M., Kharrazi, H. H. K., Fung, K. W., Fontelo, P. A., et al. (2023) · Frontiers in Artificial Intelligence · doi:10.3389/frai.2023.1229609 · Cited by 5
Zhao, T., Tang, C., Huang, Y., Wang, H., & Guo, M. (2023) · PLoS ONE · doi:10.1371/journal.pone.0287445 · Cited by 4
Pharmacological treatments in panic disorder in adults: a network meta-analysis
Guaiana, G., Barbui, C., Meader, N., Davies, S., Furukawa, T. A., Imai, H., Dias, S., Caldwell, D. M., Koesters, M., Tajika, A., et al. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012729.pub2 · Cited by 4
Muntingh, A., Batelaan, N. M., Scholten, W., & van Balkom, A. J. L. M. (2021) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.200099 · Cited by 4
Can oral formulation increase the risk of lormetazepam abuse?
Costa, E., Sterzi, E., Tedeschi, F., Casari, R., Marini, P., & Lugoboni, F. (2020) · Internal and Emergency Medicine · doi:10.1007/s11739-020-02538-2 · Cited by 4
Sertraline treatment influences [18F]FE-PE2I PET imaging for Parkinsonism
Justesen, T. E. H., Borghammer, P., Aanerud, J., Hovind, P. H., & Marner, L. (2023) · EJNMMI Research · doi:10.1186/s13550-023-01000-6 · Cited by 3
Challenges in the Design, Registration, and Reporting of Noninferiority Trials
Groenwold, R. H. H., Heerdink, E. R., & Klungel, O. H. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2021.3932 · Cited by 3
Escitalopram-Associated Tongue Hypoesthesia
Chauhan, A., & Praharaj, S. K. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001368 · Cited by 2
Hyperbolic dose reduction of escitalopram mitigates withdrawal syndrome: A case report
Gallo, A. T., & Hulse, G. K. (2022) · Psychiatry Research Case Reports · doi:10.1016/j.psycr.2022.100009 · Cited by 2
Regen, F., & Benkert, O. (2020) · Springer eBooks · doi:10.1007/978-3-662-61753-3_1 · Cited by 2
Regen, F., & Benkert, O. (2023) · Springer eBooks · doi:10.1007/978-3-662-67685-1_1 · Cited by 1
Wang, J., & Cosci, F. (2025) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253251404780 · Cited by 1
Self-citationThree Decades of SSRI/SNRI Withdrawal Research: A Bibliometric and Science-Mapping Study
Akça, E. (2025) · The European Research Journal · doi:10.18621/eurj.1825803 · Cited by 1
Ferreira, P. M., McDonald, S., Wallis, K. A., & Donald, M. (2026) · BMJ Open · doi:10.1136/bmjopen-2026-116702 · Cited by 1
Regen, F. (2026) · Springer eBooks · doi:10.1007/978-3-662-72452-1_1 · Cited by 1
Brites, R., Rodrigues, A. C., Cunha, F. C., & Ferreira, C. (2023) · Gazeta Médica · doi:10.29315/gm.v1i1.651 · Cited by 1
Maviglia, M. A., Cooeyate, N. J., Hume, D., & Guerra, L. (2024) · Journal of Psychology & Clinical Psychiatry · doi:10.15406/jpcpy.2024.15.00793 · Cited by 1
Depression and Anxiety Disorders
(2021) · Wiley eBooks · doi:10.1002/9781119870203.mpg003 · Cited by 1
The Impoverishment of Psychiatric Knowledge
Aftab, A., & Fava, G. A. (2024) · Oxford University Press eBooks · doi:10.1093/med/9780192870322.003.0005
Self-citationCetkovich, M., Abadi, A. F., Camino, S., Bonetto, G. G., Herbst, L., Marengo, E., Torrente, F. M., Maresca, T., Bustin, J., Morra, C. A., et al. (2023) · Vertex Revista Argentina de Psiquiatría · doi:10.53680/vertex.v34i159.363
Personalized psychopharmacology in integrated medical model
Krzystanek, M., Krupka-Matuszczyk, I., Trędzbor, B., Martyniak, E., Borowska, A., Stolarczyk, A., & Murawiec, S. (2023) · Psychiatria Spersonalizowana · doi:10.5114/psychs.2023.125761
Safe Deprescribing of Antidepressants
(2024) · Wiley eBooks · doi:10.1002/9781394291052.mdg002
Nakamura, T., Oe, M., Uematsu, K., Hori, H., Ozone, M., & Cosci, F. (2025) · Psychiatry and Clinical Neurosciences Reports · doi:10.1002/pcn5.70050
Self-citationBarriers to Safely Discontinuing Duloxetine: An Urgent Call to Action
Shapiro, B. B., & Cohrs, D. (2025) · CNS Drugs · doi:10.1007/s40263-025-01208-1
Additional file 1 of Sertraline treatment influences [18F]FE-PE2I PET imaging for Parkinsonism
Justesen, T. E. H., Borghammer, P., Aanerud, J., Hovind, P. H., & Marner, L. (2023) · Figshare · doi:10.6084/m9.figshare.23118916
MIMS Handbook of Psychiatric Medication
Stein, D., Hoffman, J., & Kadenge, B. (2022) · Open University of Cape Town (University of Cape Town)
Tlustošová, V. (2023) · Digitální knihovna Univerzity Pardubice (Univerzity Pardubice)
Stopping antidepressants safely
Horowitz, M. A., & Perry, T. L. (2026) · African Journal of Primary Health Care & Family Medicine · doi:10.4102/phcfm.v18i1.5431
The postpartum period and bipolar disorder: early identification, prevention, and management
Sharma, V. (2026) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2026.2653163
Strawn, J. R., & Stahl, S. M. (2026) · Cambridge University Press eBooks · doi:10.1017/9781009642187.001
Chokkakula, S., Guo, Q., Zhang, X., Jumah, J. A. B., Naveen, B., & Yang, B. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1744180
The Promise of Psychoeducation in Relieving the Societal Burden of Psychopathology
Strayhorn, J. M., Chai, K. Y. Y., & Zhang‐James, Y. (2026) · SpringerBriefs in modern perspectives on disability research. · doi:10.1007/978-981-92-0922-4
Can Drugs Relieve the Societal Burden of Psychopathology?
Strayhorn, J. M., Chai, K. Y. Y., & Zhang‐James, Y. (2026) · SpringerBriefs in modern perspectives on disability research. · doi:10.1007/978-981-92-0922-4_4
Cuevas, C. D. L. (2026) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.70604
Pharmacotherapy for social anxiety disorder: An evidence-based treatment review
Strawn, J. R., Stahl, S. M., Nasser, A. F., Cutler, A. J., & Bernik, M. (2026) · CNS Spectrums · doi:10.1017/s1092852926101254
Zolnour, A., Eldredge, C. E., Faiola, A., Yaghoobzadeh, Y., Khani, M., Foy, D., Topaz, M., Kharrazi, H., Fung, K. W., Fontelo, P., et al. (2023) · doi:10.3389/frai.2023.1229609.s001
Metadata
- Authors
- Fava, G. A., & Cosci, F.
- Affiliations
- Erie County Medical Center (US)
- University of Florence (IT)
- Corresponding author
- Fava, Giovanni A.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2019-11-26
- Volume
- 80
- Issue
- 6
- ISSN
- 0160-6689 (ISSN-L)
- 1555-2101
- OpenAlex
- W2990135086
- Cited by
- 69
- References
- 40
- Citations by year
- 2026: 9 · 2025: 6 · 2024: 8 · 2023: 15 · 2022: 11 · 2021: 10 · 2020: 9 · 2019: 1
- FWCI
- 4.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Florence Research (University of Florence) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- antidepressant withdrawal syndrome, antidepressant discontinuation, antidepressant tapering, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, antidepressant switching, treatment refractoriness, behavioral toxicity
- MeSH terms
- Antidepressive Agents, Drug Administration Schedule, Drug Therapy, Combination, Humans, Metabolic Clearance Rate, Risk Factors, Substance Withdrawal Syndrome, Syndrome, Retreatment, Drug Substitution
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.